Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sputum proteomic signature of gastro-oesophageal reflux in patients with severe asthma.

Respiratory medicine·2019
Same author

8-isoprostane in exhaled breath condensate after experimental exposure to wood smoke in humans.

Journal of biological regulators and homeostatic agents·2016
Same author

Exhaled breath condensate, nasal eosinophil cationic protein level and nasal cytology during immunotherapy for cypress allergy.

Journal of biological regulators and homeostatic agents·2014
Same author

Long-acting beta-agonists and their association with inhaled corticosteroids in COPD.

Current medicinal chemistry·2013
Same author

Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD.

Current medicinal chemistry·2012
Same author

Non-invasive biomarkers of lung inflammation in smoking subjects.

Current medicinal chemistry·2012

Related Experiment Video

Updated: Jun 6, 2026

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
13:45

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Published on: December 23, 2010

Leukotriene modifiers for asthma treatment.

P Montuschi1, M L Peters-Golden

  • 1Department of Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy. pmontuschi@rm.unicatt.it

Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|November 10, 2010
PubMed
Summary

Leukotriene modifiers offer potential benefits for asthma management by targeting cysteinyl leukotriene receptor 1 (CysLT1). Combination therapy may improve asthma control and reduce inhaled corticosteroid doses.

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Related Experiment Videos

Last Updated: Jun 6, 2026

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
13:45

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Published on: December 23, 2010

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Area of Science:

  • Pulmonology
  • Immunology
  • Pharmacology

Background:

  • Leukotrienes (LTs) are key lipid mediators in asthma pathophysiology.
  • Cysteinyl LTs (CysLTs) act via CysLT1 and CysLT2 receptors, with CysLT1 activation driving major asthma symptoms.
  • LTB(4) may contribute to severe asthma, exacerbations, and airway hyperresponsiveness.

Purpose of the Study:

  • To review the role of leukotrienes in asthma.
  • To discuss the therapeutic applications of leukotriene modifiers in asthma treatment.

Main Methods:

  • Literature review of leukotriene roles and modifier efficacy in asthma.
  • Analysis of CysLT1 receptor antagonist mechanisms and clinical outcomes.

Main Results:

  • CysLT1 receptor antagonists are effective oral monotherapy for mild persistent asthma but less so than inhaled glucocorticoids.
  • Combination therapy with CysLT1 antagonists and inhaled glucocorticoids can enhance asthma control and allow for reduced glucocorticoid dosage.
  • Patient subgroup identification is crucial due to variable responses to CysLT1 antagonists.
  • CysLT1 antagonists show potential anti-remodeling effects, possibly preventing or reversing airway structural changes.

Conclusions:

  • Leukotriene modifiers, particularly CysLT1 receptor antagonists, represent a valuable therapeutic option in asthma management.
  • Personalized treatment strategies considering patient subgroups and potential anti-remodeling effects are important for optimizing asthma care.